Drug intelligence / Profile preview

THUR-24

Development stage: Preclinical
Lead developer: Thuris
Modality: Small Molecules

Overview

THUR-24 is an experimental drug candidate developed by Thuris Corp for the treatment of Alzheimer's disease. It is designed to target the Amyloid Precursor Protein (APP), a critical protein in the pathogenesis of Alzheimer's whose proteolytic processing leads to the formation of neurotoxic amyloid-beta peptides. By modulating or inhibiting the expression or processing of APP, THUR-24 aims to reduce the accumulation of amyloid plaques in the brain, thereby potentially slowing or halting disease progression. The drug is currently in the pre-clinical or IND-enabling stage of development.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on THUR-24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THUR-24.

Explore the full profile